EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics

Dario Pitocco iD, Martina Cortelletti, Giovanna Petrucci iD, Bianca Rocca iD

European Cardiology Review · 02.06.2026

DOI: 10.15420/ecr.2025.99 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 02.06.2026. Verfasst von Dario Pitocco und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Care Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Catholic University Rome, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity, especially moderate-to-severe obesity, is strongly associated with multimorbidity, especially cardiovascular diseases, and polypharmacy. Patients with moderate to severe obesity are under-represented in large trials, so current dosing strategies are largely extrapolated from populations without obesity. Moderate and severe obesity induce complex and dynamic alterations in the gastrointestinal tract, liver and kidneys, which may affect a drug’s pharmacokinetic actions of absorption, distribution, metabolism and excretion. Drug distribution and exposure may also differ based on lipophilicity. Multimorbid patients with obesity and cardiovascular disease are frequently prescribed polypharmacy. Polypharmacy increases the risk of pharmacokinetic-based drug–drug interactions often mediated by the cytochrome P450 enzymes, whose activity can be modified by obesity. Therefore, drug response can be highly and unpredictably variable. New incretin-based therapies can affect the pharmacokinetics of orally co-administered drugs by modifying the gastrointestinal physiology. We review obesity-related pharmacokinetic changes, focusing on common cardiovascular medications. A pragmatic, personalised approach is proposed to reduce variability in response, which may ultimately improve safety and effectiveness.

Schlagwörter

Stichwörter der Autor:innen

Obesityanticoagulantantiplateletblood pressure-lowering drugscardiovascular diseasespharmacokinetics

Autor:innen und Institutionen

  • Diabetes Care Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS Catholic University Rome, Italy.
  • Hospital Pharmacy Unit, Ente Ecclesiastico Ospedale Generale Regionale F Miulli Acquaviva delle Fonti, Italy.
  • Departmental Faculty of Medicine, UniCamillus - Saint Camillus International University of Health and Medical Sciences Rome, Italy.
  • Department of Medicine and Surgery, LUM University Casamassima, Italy.

ORCID-Profile: Dario Pitocco, Giovanna Petrucci, Bianca Rocca

Zitieren

APA

Pitocco, D., Cortelletti, M., Petrucci, G., & Rocca, B. (2026). Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics. European Cardiology Review. https://doi.org/10.15420/ecr.2025.99

Vancouver

Pitocco D, Cortelletti M, Petrucci G, Rocca B. Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics. European Cardiology Review. 2026. doi:10.15420/ecr.2025.99

BibTeX
@article{Pitocco2026,
  author = {Pitocco, Dario and Cortelletti, Martina and Petrucci, Giovanna and Rocca, Bianca},
  title = {Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics},
  journal = {European Cardiology Review},
  year = {2026},
  doi = {10.15420/ecr.2025.99}
}
Kostenlos starten →